FGF21 and metabolic dysfunction-associated steatohepatitis: Furthermore, FGF21 analogues have been studied both in animal and human models as therapeutics for obesity, T2D, hyperlipidemia, and nonalcoholic steatohepatitis [31, 44-47, 55-60].